Trial Profile

Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Neratinib (Primary) ; Trastuzumab emtansine (Primary)
Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Male breast cancer
Focus Pharmacodynamics

Most Recent Events

31 Jan 2025 Planned End Date changed from 1 Jul 2025 to 1 Jul 2026.
31 Jan 2025 Planned primary completion date changed from 1 Jul 2025 to 1 Jul 2026.
06 Jun 2023 Status changed from not yet recruiting to recruiting as per trial design, presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com